A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance
about
Mechanisms of resistance to anti-EGFR therapy in colorectal cancerSynergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR geneThe Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment.Intratumor heterogeneity and its impact on drug distribution and sensitivity.Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors.Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.
P2860
Q28074073-D4F40EE3-12C8-451F-8F75-C02D01E5E2E6Q35619189-1F4AEB16-16D8-4CE0-A75B-DD4C7047776AQ35681816-D4D6FE74-04C2-472B-A57A-AF5C5EBA6EAAQ35905710-C56DD119-EB72-439E-B47D-98D5FE93FEBCQ36243533-A5FE1089-25FC-4881-9BA9-3C6250B01F1BQ36254653-A3024D96-F7F6-43B6-A633-DF6AAAD9E2D5Q36291109-B29D059D-77A2-4D1A-BCDD-F4E98E571207Q36814881-D8FFCC3A-BEA4-450F-9809-88CBEB39BA45Q37684771-07A84877-7DB4-41BF-BDA6-64955E3F0817Q38211694-8E928C58-DC9C-4B7D-A1A4-146F43A85FD6Q38586993-B202C890-B20B-4520-9E0E-0D22F71CAE4DQ38687571-97FF4E02-974A-446B-BE80-360F1ACFEB4AQ38717594-1ABBE374-467E-4A8B-BA9F-3E064CA0C053Q38838740-39F91727-4B8D-4FE7-9F59-63952C41654BQ39022069-48B4E069-A9CE-4DEC-87B0-9F94438E2D63Q39054011-3A47E430-BE7E-4D35-AB6E-90E70733CCA2Q39173405-E675B1E6-A1CD-4830-9C87-6B22009B5086Q40465701-47DE0AB6-5C67-4AA7-8ACB-90593433A9E7Q41276800-B575E3FC-6EE8-4BAC-86A5-6402C508B751Q47780922-D844C29D-E659-4947-A951-3AF73556903EQ54166640-1455CC8F-945B-4F47-BE25-FE400AB72408
P2860
A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A pilot study of preoperative ...... s mediating primary resistance
@ast
A pilot study of preoperative ...... s mediating primary resistance
@en
type
label
A pilot study of preoperative ...... s mediating primary resistance
@ast
A pilot study of preoperative ...... s mediating primary resistance
@en
prefLabel
A pilot study of preoperative ...... s mediating primary resistance
@ast
A pilot study of preoperative ...... s mediating primary resistance
@en
P2093
P2860
P1476
A pilot study of preoperative ...... s mediating primary resistance
@en
P2093
Aaron Becker
Alberto Chiappori
Eric B Haura
Eric Sommers
Lanxi Song
P2860
P304
P356
10.1097/JTO.0B013E3181F38F70
P577
2010-11-01T00:00:00Z